Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Carcinoma
Interventions:   Drug: Camrelizumab;   Drug: Placebos;   Drug: Gemcitabine;   Drug: Cisplatin
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting

https://ift.tt/2EmUpBn